- Stocks
- Pharma & Healthcare
- Gennex Labs
Gennex Labs share price
NSE: GENNEXPharma & HealthcareDrug Manufacturers - Specialty & Generic
Gennex Labs at a glance
With a market capitalisation of ₹254 Cr, it ranks 2133rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 9.4% in FY26. In Q2 FY24, the quarter ended 30 Sep 2023, revenue was ₹20 Cr and net profit −₹1 Cr, on a consolidated basis. Promoters held 23.63% of the company as of 30 Jun 2026; 21.77% of promoter shares were pledged.
Key numbers
- Market cap
- ₹254 CrRank 2133 on NSE
- Price to book
- 0.78×FY26
- ROE
- 9.4%FY26
- ROCE
- 9.9%FY26
- Debt to equity
- 0.16FY26
- Net profit margin
- 12.1%FY26
- Book value / share
- ₹9.16FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Gennex Labs quarterly results
| Quarter | Q1 FY24 | Q2 FY24 |
|---|---|---|
| Revenue | ₹26 Cr | ₹20 Cr |
| Revenue YoY | — | — |
| Net profit | ₹2 Cr | −₹1 Cr |
| Net profit YoY | — | — |
| Net margin | 7.9% | −3.5% |
| EPS | ₹1.53 | −₹0.53 |
Gennex Labs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹60 Cr | ₹61 Cr | ₹66 Cr | ₹87 Cr | ₹138 Cr | — |
| Operating profit | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹16 Cr | ₹22 Cr | — |
| Net profit | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹13 Cr | ₹18 Cr | — |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹0.00 | ₹1.00 | ₹1.00 | — |
| Cash from operations | −₹1 Cr | ₹7 Cr | ₹24 Cr | −₹47 Cr | −₹11 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹40 Cr | ₹44 Cr | ₹80 Cr | ₹170 Cr | ₹187 Cr | ₹223 Cr |
Gennex Labs shareholding pattern
| Holder | 4 Jul 2025 | 8 Jul 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 21.85% | 23.62% | 23.62% | 23.62% | 23.63% | 23.63% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 78.15% | 76.38% | 76.38% | 76.38% | 76.37% | 76.37% |
| Promoter shares pledged | 19.27% | 17.43% | 17.43% | 17.43% | 17.42% | 21.77% |
Gennex Labs vs peers
The listed Pharma & Healthcare companies nearest to Gennex Labs by market capitalisation.
Ask anything about Gennex Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against GENNEX's own history. Try: “Why has GENNEX moved over the last three months?” · “Backtest a 50-day moving-average crossover on GENNEX over five years” · “Compare GENNEX with ESPIRE on margins and valuation”
Frequently asked questions about Gennex Labs
What is the market cap of Gennex Labs?
Gennex Labs' market capitalisation is ₹254 Cr (₹254 Cr) at the 22 Oct 2026 close, ranking 2133rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Gennex Labs?
Return on equity was 9.4% in FY26 and return on capital employed was 9.9% in FY26 (consolidated figures).
Is Gennex Labs a debt-free company?
No. Gennex Labs' debt-to-equity ratio was 0.16 in FY26, with total debt of ₹0 Cr.
What were Gennex Labs' latest quarterly results?
For Q2 FY24 (quarter ended 30 Sep 2023), Gennex Labs reported revenue of ₹20 Cr and net profit of −₹1 Cr.
What is the shareholding pattern of Gennex Labs?
As of 30 Jun 2026: promoters 23.63%, domestic institutions 0.00%, non-institutions 76.37%. 21.77% of promoter shares were pledged.
Who are Gennex Labs' competitors?
The listed Pharma & Healthcare companies closest to Gennex Labs by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Kerala Ayur, Nath Bio-Genes (India) and BDH Industries.
Is Gennex Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gennex Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GENNEX against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text